Interaction between endogenous opioids and IL-2 on PHA-stimulated human lymphocytes

Neil Elliot Kay, J. E. Morley, J. I. Allen

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Endogenous opioids exert a variety of extra central nervous system (CNS) functions, including modulation of some human lymphocyte functions. The latter opioid activity may result in elevation of human natural killer (NK) function (i.e. by β-endorphin), which is reversed by an opioid antagonist, Naloxone. Since recent evidence has suggested both structural and functional similarities between lymphokines known to elevate human NK function (interferon and interleukin-2) and endogenous opioids, we investigate if Naloxone could modulate lymphokine-enhanced huma NK activity. Naloxone blunted, in a dose-dependent fashion, the NK-enhancing activity of peripheral blood lymphocytes or large granular lymphocytes by recombinant interferon-alpha (IFN-α) or interleukin-2 (IL-2). Naloxone decreased the uptake of radiolabelled IL-2 receptors. β-endorphin also decreased the binding of radiolabelled IL-2 or IL-2 receptor-positive human lymphocytes. Finally, labelled Naloxone was inhibited from binding to phytohaemagglutinin (PHA)-stimulated lymphocytes by either β-endorphin or IL-2. These findings strongly suggest that human lymphocyte receptors for opioid, IFN or IL-2 molecules, once occupied, have distinct influences on the alternate receptor. In addition, these data further strengthen the potential role of CNS-mediated influences of the human immune system.

Original languageEnglish (US)
Pages (from-to)485-491
Number of pages7
JournalImmunology
Volume70
Issue number4
StatePublished - 1990
Externally publishedYes

Fingerprint

Phytohemagglutinins
Opioid Analgesics
Interleukin-2
Naloxone
Lymphocytes
Endorphins
Lymphokines
Interleukin-2 Receptors
Central Nervous System
Narcotic Antagonists
Opioid Receptors
Interferon-alpha
Interferons
Immune System

ASJC Scopus subject areas

  • Immunology

Cite this

Interaction between endogenous opioids and IL-2 on PHA-stimulated human lymphocytes. / Kay, Neil Elliot; Morley, J. E.; Allen, J. I.

In: Immunology, Vol. 70, No. 4, 1990, p. 485-491.

Research output: Contribution to journalArticle

Kay, Neil Elliot ; Morley, J. E. ; Allen, J. I. / Interaction between endogenous opioids and IL-2 on PHA-stimulated human lymphocytes. In: Immunology. 1990 ; Vol. 70, No. 4. pp. 485-491.
@article{f0fbe6d959324bba9fa48be531e82b6c,
title = "Interaction between endogenous opioids and IL-2 on PHA-stimulated human lymphocytes",
abstract = "Endogenous opioids exert a variety of extra central nervous system (CNS) functions, including modulation of some human lymphocyte functions. The latter opioid activity may result in elevation of human natural killer (NK) function (i.e. by β-endorphin), which is reversed by an opioid antagonist, Naloxone. Since recent evidence has suggested both structural and functional similarities between lymphokines known to elevate human NK function (interferon and interleukin-2) and endogenous opioids, we investigate if Naloxone could modulate lymphokine-enhanced huma NK activity. Naloxone blunted, in a dose-dependent fashion, the NK-enhancing activity of peripheral blood lymphocytes or large granular lymphocytes by recombinant interferon-alpha (IFN-α) or interleukin-2 (IL-2). Naloxone decreased the uptake of radiolabelled IL-2 receptors. β-endorphin also decreased the binding of radiolabelled IL-2 or IL-2 receptor-positive human lymphocytes. Finally, labelled Naloxone was inhibited from binding to phytohaemagglutinin (PHA)-stimulated lymphocytes by either β-endorphin or IL-2. These findings strongly suggest that human lymphocyte receptors for opioid, IFN or IL-2 molecules, once occupied, have distinct influences on the alternate receptor. In addition, these data further strengthen the potential role of CNS-mediated influences of the human immune system.",
author = "Kay, {Neil Elliot} and Morley, {J. E.} and Allen, {J. I.}",
year = "1990",
language = "English (US)",
volume = "70",
pages = "485--491",
journal = "Immunology",
issn = "0019-2805",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Interaction between endogenous opioids and IL-2 on PHA-stimulated human lymphocytes

AU - Kay, Neil Elliot

AU - Morley, J. E.

AU - Allen, J. I.

PY - 1990

Y1 - 1990

N2 - Endogenous opioids exert a variety of extra central nervous system (CNS) functions, including modulation of some human lymphocyte functions. The latter opioid activity may result in elevation of human natural killer (NK) function (i.e. by β-endorphin), which is reversed by an opioid antagonist, Naloxone. Since recent evidence has suggested both structural and functional similarities between lymphokines known to elevate human NK function (interferon and interleukin-2) and endogenous opioids, we investigate if Naloxone could modulate lymphokine-enhanced huma NK activity. Naloxone blunted, in a dose-dependent fashion, the NK-enhancing activity of peripheral blood lymphocytes or large granular lymphocytes by recombinant interferon-alpha (IFN-α) or interleukin-2 (IL-2). Naloxone decreased the uptake of radiolabelled IL-2 receptors. β-endorphin also decreased the binding of radiolabelled IL-2 or IL-2 receptor-positive human lymphocytes. Finally, labelled Naloxone was inhibited from binding to phytohaemagglutinin (PHA)-stimulated lymphocytes by either β-endorphin or IL-2. These findings strongly suggest that human lymphocyte receptors for opioid, IFN or IL-2 molecules, once occupied, have distinct influences on the alternate receptor. In addition, these data further strengthen the potential role of CNS-mediated influences of the human immune system.

AB - Endogenous opioids exert a variety of extra central nervous system (CNS) functions, including modulation of some human lymphocyte functions. The latter opioid activity may result in elevation of human natural killer (NK) function (i.e. by β-endorphin), which is reversed by an opioid antagonist, Naloxone. Since recent evidence has suggested both structural and functional similarities between lymphokines known to elevate human NK function (interferon and interleukin-2) and endogenous opioids, we investigate if Naloxone could modulate lymphokine-enhanced huma NK activity. Naloxone blunted, in a dose-dependent fashion, the NK-enhancing activity of peripheral blood lymphocytes or large granular lymphocytes by recombinant interferon-alpha (IFN-α) or interleukin-2 (IL-2). Naloxone decreased the uptake of radiolabelled IL-2 receptors. β-endorphin also decreased the binding of radiolabelled IL-2 or IL-2 receptor-positive human lymphocytes. Finally, labelled Naloxone was inhibited from binding to phytohaemagglutinin (PHA)-stimulated lymphocytes by either β-endorphin or IL-2. These findings strongly suggest that human lymphocyte receptors for opioid, IFN or IL-2 molecules, once occupied, have distinct influences on the alternate receptor. In addition, these data further strengthen the potential role of CNS-mediated influences of the human immune system.

UR - http://www.scopus.com/inward/record.url?scp=0025112685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025112685&partnerID=8YFLogxK

M3 - Article

C2 - 2394465

AN - SCOPUS:0025112685

VL - 70

SP - 485

EP - 491

JO - Immunology

JF - Immunology

SN - 0019-2805

IS - 4

ER -